BidaskClub upgraded shares of Grifols SA, Barcelona (NASDAQ:GRFS) from a strong sell rating to a sell rating in a report issued on Wednesday.
GRFS has been the topic of several other reports. Zacks Investment Research downgraded shares of Grifols SA, Barcelona from a buy rating to a hold rating in a research report on Wednesday, October 11th. Citigroup started coverage on shares of Grifols SA, Barcelona in a report on Tuesday, October 31st. They set a buy rating on the stock. Finally, UBS downgraded shares of Grifols SA, Barcelona from an outperform rating to a market perform rating in a report on Friday, November 24th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of Hold and a consensus price target of $24.00.
Shares of Grifols SA, Barcelona (GRFS) traded down $0.14 during mid-day trading on Wednesday, reaching $21.95. 193,900 shares of the company traded hands, compared to its average volume of 620,540. Grifols SA, Barcelona has a one year low of $15.47 and a one year high of $24.20. The stock has a market cap of $15,083.56, a P/E ratio of 20.45, a price-to-earnings-growth ratio of 1.66 and a beta of 1.04. The company has a quick ratio of 1.39, a current ratio of 3.17 and a debt-to-equity ratio of 1.69.
ILLEGAL ACTIVITY NOTICE: “Grifols SA, Barcelona (GRFS) Upgraded to “Sell” at BidaskClub” was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.com-unik.info/2017/12/21/grifols-sa-barcelona-grfs-upgraded-to-sell-at-bidaskclub.html.
Grifols SA, Barcelona Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.
What are top analysts saying about Grifols SA Barcelona? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Grifols SA Barcelona and related companies.